German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma

Annals of Neurology

Volumn 51, Issue 2, 2002, Pages 247-252

  Herrlinger, Ulrich ^a   Schabet, Martin ^b   Brugger, Wolfram ^a   Kortmann, Rolf Dieter ^a   Küker, Wilhelm ^a   Deckert, Martina ^a   Engel, Corinna ^c   Schmeck Lindenau, Hans Jürgen ^d   Mergenthaler, Hans Günther ^e   Krauseneck, Peter ^f   Benöhr, Christian ^g   Meisner, Christoph ^f   Wiestler, Otmar D ^a   Dichgans, Johannes ^b   Kanz, Lothar ^a   Bamberg, Michael ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KLINIKUM LUDWIGSBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Inst for Med Info Processing   (Germany)

^e Klinikum Reinkenheide   (Germany)

^f Katharinenhospital ^*  (Germany)

^g Department of Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; METHOTREXATE; PROCARBAZINE; STEROID; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENCE; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036156960     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10102     Document Type: Article

References (19)

1. Non-Hodgkin's lymphoma of the brain: Can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315
2. Combined modality therapy for primary CNS lymphoma
3. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome
4. Long-term survival in primary CNS lymphoma
5. Treatment of primary CNS lymphoma: The next step
6. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
7. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
8. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature
9. Primary CNS lymphoma 1991-1997: Outcome and late adverse effects after combined modality treatment
10. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
11. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors
12. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
13. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma. Response to therapy and quality of life of patients
14. High-dose methotrexate for primary CNS lymphoma in the elderly
15. The treatment of primary central nervous lymphoma (PCNSL) with methotrexate and deferred radiotherapy: NABTT 96-07
16. Response criteria for phase II studies of supratentorial malignant glioma
17. Non-parametric estimations from incomplete observations
18. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia